Your browser doesn't support javascript.
loading
Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
Bril, S I; Chargi, N; Wendrich, A W; Wegner, I; Bol, G H; Smid, E J; de Jong, P A; Devriese, L A; de Bree, R.
Afiliação
  • Bril SI; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Chargi N; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Wendrich AW; Department of Otorhinolaryngology - Head and Neck Surgery University Medical Center Utrecht, Utrecht, the Netherlands.
  • Wegner I; Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Groningen, Groningen, the Netherlands.
  • Bol GH; Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
  • Smid EJ; Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
  • de Jong PA; Department of Radiology and Nuclear Medicine, Division of Imaging and Oncology, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
  • Devriese LA; Department of Medical Oncology, Division of Imaging and Oncology, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
  • de Bree R; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: r.debree@umcutrecht.nl.
Oral Oncol ; 123: 105617, 2021 12.
Article em En | MEDLINE | ID: mdl-34749251
ABSTRACT

BACKGROUND:

Low skeletal muscle mass (SMM) is associated with adverse outcomes. SMM is often assessed at the third lumbar vertebra (L3) on abdominal imaging. Abdominal imaging is not routinely performed in patients with head and neck cancer (HNC). We aim to validate SMM measurement at the level of the third cervical vertebra (C3) on head and neck imaging. MATERIAL AND

METHODS:

Patients with pre-treatment whole-body computed tomography (CT) between 2010 and 2018 were included. Cross-sectional muscle area (CSMA) was manually delineated at the level of C3 and L3. Correlation coefficients and intraclass correlation coefficients (ICCs) were calculated. Cohen's kappa was used to assess the reliability of identifying a patient with low SMM.

RESULTS:

Two hundred patients were included. Correlation between CSMA at the level of C3 and L3 was good (r = 0.75, p < 0.01). Using a multivariate formula to estimate CSMA at L3, including gender, age, and weight, correlation improved (r = 0.82, p < 0.01). The agreement between estimated and actual CSMA at L3 was good (ICC 0.78, p < 0.01). There was moderate agreement in the identification of patients with low SMM based on the estimated lumbar skeletal muscle mass index (LSMI) and actual LSMI (Cohen's κ 0.57, 95%CI 0.45-0.69).

CONCLUSIONS:

CSMA at C3 correlates well with CSMA at L3. There is moderate agreement in the identification of patients with low SMM based on the estimated lumbar SMI (based on measurement at C3) and actual LSMI.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcopenia / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcopenia / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2021 Tipo de documento: Article